Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
sacituzumab govitecan
antibody-drug conjugate (ADC), anti-Trop-2, topoisomerase I inhibitor · anticancer
antibody-drug conjugate (ADC), anti-Trop-2, topoisomerase I inhibitoranticancer
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
- BosentanSevereDatabaseDDInter
Mechanism
Sacituzumab govitecan is a Trop-2–directed antibody conjugated to a camptothecin derivative (topoisomerase I inhibitor).
Indications
metastatic triple-negative breast cancermetastatic urothelial cancer
Side effects
Serious
- severe neutropenia
- severe diarrhea
Drug interactions
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bosentan
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Dacomitinib
Severe
Database
Clinical effect not specified
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Eslicarbazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about sacituzumab govitecan
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team